MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: The company manufactures medical devices, including custom kits, stand-alone devices, inflation devices, and catheters. Management reported record revenues and earnings for the quarter and the nine-month period, driven by market share gains, increased hospital procedures, and improved manufacturing efficiency.

Key Financial Metrics

Note: Working Capital calculated as Total Current Assets ($42,517,481) minus Total Current Liabilities ($13,040,762).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14% in the third quarter and 11% for the nine-month period compared to 2001. Growth was broad-based, with stand-alone devices up 22% (Q3) and custom kits up 17% (Q3).
• Margin Expansion: Gross margin improved significantly from 37.9% to 42.8% in Q3 and from 36.0% to 41.2% for the nine-month period. This was attributed to higher labor/overhead productivity and cost reduction programs.
• Profitability: Operating income rose 69% in Q3 and 76% for the nine-month period. Net income increased 79% in Q3 and 70% for the nine-month period.
• Debt Reduction: The company paid down approximately $5.8 million in long-term debt during the nine-month period. The outstanding balance on the revolving credit facility was reduced to zero.
• Liquidity: Cash and cash equivalents increased by $6.1 million during the nine-month period, rising from $341,690 at the beginning of the period to $6.4 million.

Guidance, Outlook, and Risks

Management Commentary: Management expects continued improvement in financial performance, though at a more gradual pace than the previous year as many cost-reduction initiatives have already been realized. The company is in a stronger position to invest in long-term growth and expanded products.

Capital Expenditures: Capital expenditures were $6.6 million for the nine months ended September 30, 2002. Management anticipates potential increases in plant capacity in Ireland and Utah starting in 2003 or 2004.

Risks and Contingencies:

• Market Volatility: Stock price may be volatile due to general economic conditions, interest rates, or failure to meet analyst expectations.
• Competition: The market is highly competitive with larger, better-established companies.
• Regulatory: Products are subject to FDA regulation; failure to comply could adversely affect the business.
• Reimbursement: Limits on government or insurance reimbursement could reduce hospital purchasing power.
• Foreign Currency: Fluctuations in foreign currencies (primarily the Euro) could result in transaction losses, though a limited hedging program is in place.
• Key Personnel: Success depends on key management, specifically Chairman and CEO Fred P. Lampropoulos.

Investor Verification Checklist

• Debt Status: Verify the complete payoff of the revolving credit facility and the remaining balance of long-term debt ($87,431).
• Inventory Levels: Confirm the reduction in inventory ($20.2 million) and the adequacy of the obsolescence reserve ($3.7 million) given the company's focus on inventory reduction.
• Margin Sustainability: Assess whether the improved gross margins (42.8%) are sustainable or driven by temporary efficiency gains.
• Cash Flow Utilization: Monitor how the substantial cash balance ($6.4 million) will be deployed, particularly regarding future capital expenditures in Ireland and Utah.
• Product Mix: Verify continued growth in high-margin custom kits and stand-alone devices versus inflation devices and catheters.